Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 5 SUPPL., 2013, Pages 663-666

  Radich, Jerald P ^a  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERFERON;

CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOGENETICS; GASTROINTESTINAL TOXICITY; HUMAN; MUTATIONAL ANALYSIS; ONCOLOGY; OVERALL SURVIVAL; PRACTICE GUIDELINE; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84887433301     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0196     Document Type: Conference Paper

References (11)

1. Quintás-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973-988.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five years follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
3. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood 2009;114(Suppl): Abstract 1126.
4. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-2203.
5. Hochhaus A, Shah NP, Cortes JE, et al. Dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: DASISION 3-year follow-up [abstract]. J Clin Oncol 2012;30(Suppl 15): Abstract 6504.
6. Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw 2012;10(Suppl 3):S1-S13.
7. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
8. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure of suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437-4444.
9. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained completed molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
10. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation [abstract]. J Clin Oncol 2012;30(Suppl 15): Abstract 6503.
11. Gambacorti-Passerini C, Lipton JH, Tee GY, et al. BELA trial update: bosutinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia after 30 months of follow-up [abstract]. J Clin Oncol 2012;30(Suppl 15): Abstract 6512